Stock Code: 002370 Stock Abbreviation: Asia-Pacific Pharmaceutical Announcement No.: 2026-033 Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Announcement on the Company's Application for Comprehensive Credit Line from Banks The Company and all members of the Board of Directors guarantee the information disclosed is true, accurate, and complete, and free from false representations, misleading statements, or material omissions. Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Asia-Pacific Pharmaceutical") held the twelfth meeting of the eighth Board of Directors on April 23, 2026, and deliberated and approved the "Proposal on the Company's Application for Comprehensive Credit Line from Banks." The specific details are hereby announced as follows: I. Overview of the Current Credit Line Application In accordance with the Company's strategic development plan and capital utilization arrangements, the Company intends to apply for a comprehensive credit line from banks not exceeding RMB 300 million. The scope of credit includes, but is not limited to, working capital loans, fixed-asset loans, bank acceptance drafts, letters of credit, guarantees, and bill discounts, bill pools, etc. The specific banks, corresponding credit lines, and credit products will be subject to the formal agreements finally signed by the Company with the banks. The aforementioned comprehensive credit line does not represent the actual financing amount. The actual financing amount will be based on the Company's actual demand for operating capital within the credit line and the actual financing amount occurring with the banks. As of the disclosure date of this announcement, the Company has not yet signed relevant agreements with the banks. The Board of Directors proposes to authorize the General Manager or the Financial Controller to handle relevant procedures on behalf of the Company within the authorized credit line and to sign contracts, agreements, and other legal documents related to the aforementioned credit. The term of this credit line will be from the date of approval by the 2025 Annual General Meeting of Shareholders to the date of the 2026 Annual General Meeting of Shareholders. The credit line can be used in a revolving manner within the authorized period. II. Deliberation Procedures The Company held the twelfth meeting of the eighth Board of Directors on April 23, 2026. The meeting deliberated and approved the "Proposal on the Company's Application for Comprehensive Credit Line from Banks" with 9 votes in favor, 0 votes against, and 0 abstentions. In accordance with the "Shenzhen Stock Exchange Stock Listing Rules," "Shenzhen Stock Exchange Listing Supervision Guide No. 1 - Normative Operation of Main Board Listed Companies," and other relevant laws, regulations, and the "Articles of Association," this matter needs to be submitted to the Company's Shareholders' Meeting for deliberation. III. Documents for Reference
- Resolution of the twelfth meeting of the eighth Board of Directors Hereby announced. Zhejiang Asia-Pacific Pharmaceutical Co., Ltd. Board of Directors April 25, 2026